Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Taylor-Rowan, Martin; Alharthi, Ahmed A; Noel-Storr, Anna H; Myint, Phyo K; Stewart, Carrie; McCleery, Jenny; Quinn, Terry J

doi:10.1002/14651858.cd015405.pub2

Cochrane Database of Systematic Reviews

2023

DOI: 10.1002/14651858.cd015405.pub2

|View full text |Cite

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Martin Taylor-Rowan,

Ahmed A Alharthi,

Anna H Noel-Storr

et al.

Abstract: Cochrane Database of Systematic Reviews Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment (Protocol)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 59 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

Lundby,

Farrell,

Wilson

2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

Anticholinergic‐induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76‐year‐old woman who experienced significant cognitive improvement following deprescribing long‐term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely.

show abstract

Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

Lundby,

Farrell,

Wilson

2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Abstract: Cochrane Database of Systematic Reviews Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment (Protocol)

Cited by 1 publication

References 59 publications

Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

Contact Info

Product

Resources

About